ProShare Advisors
VIR icon

ProShare Advisors’s Vir Biotechnology VIR Stock Holding History

ProShare Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
23,043
+1,275
+6% +$12.1K ﹤0.01% 1555
2026
Q1 		$195K Sell
21,768
-1,757
-7% -$14K ﹤0.01% 1590
2025
Q4 		$142K Buy
23,525
+1,705
+8% +$10.2K ﹤0.01% 1808
2025
Q3 		$125K Sell
21,820
-3,285
-13% -$16.8K ﹤0.01% 1804
2025
Q2 		$127K Sell
25,105
-2,486
-9% -$13.3K ﹤0.01% 1824
2025
Q1 		$179K Sell
27,591
-5,972
-18% -$53.1K ﹤0.01% 1721
2024
Q4 		$246K Buy
33,563
+6,767
+25% +$53.4K ﹤0.01% 1768
2024
Q3 		$201K Buy
26,796
+5,441
+25% +$47.3K ﹤0.01% 1730
2024
Q2 		$190K Sell
21,355
-5,037
-19% -$48.3K ﹤0.01% 1540
2024
Q1 		$267K Buy
26,392
+2,035
+8% +$20.7K ﹤0.01% 1501
2023
Q4 		$245K Buy
24,357
+2,789
+13% +$25.5K ﹤0.01% 1522
2023
Q3 		$202K Buy
21,568
+13
+0.1% +$185 ﹤0.01% 1458
2023
Q2 		$529K Buy
21,555
+1,693
+9% +$42.5K ﹤0.01% 921
2023
Q1 		$462K Sell
19,862
-3,841
-16% -$98.2K ﹤0.01% 947
2022
Q4 		$600K Buy
23,703
+1,288
+6% +$31.6K ﹤0.01% 879
2022
Q3 		$431K Buy
22,415
+619
+3% +$15.7K ﹤0.01% 965
2022
Q2 		$556K Sell
21,796
-4,843
-18% -$113K ﹤0.01% 905
2022
Q1 		$685K Sell
26,639
-6,759
-20% -$200K ﹤0.01% 1097
2021
Q4 		$1.4M Sell
33,398
-3,941
-11% -$154K ﹤0.01% 879
2021
Q3 		$1.63M Sell
37,339
-4,018
-10% -$174K ﹤0.01% 764
2021
Q2 		$1.96M Buy
41,357
+8,126
+24% +$369K 0.01% 730
2021
Q1 		$1.7M Buy
33,231
+536
+2% +$28.9K 0.01% 753
2020
Q4 		$876K Buy
32,695
+25,010
+325% +$813K ﹤0.01% 945
2020
Q3 		$264K Buy
7,685
+1,259
+20% +$54.2K ﹤0.01% 1264
2020
Q2 		$263K Buy
+6,426
New +$216K ﹤0.01% 1300

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ProShare Advisors's VIR Position: Q2 2026 in Review

ProShare Advisors increased its Vir Biotechnology (VIR) stake by 5.9% in Q2 2026, buying an estimated $12.1K and bringing the position to 23,043 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1555.

ProShare Advisors first reported a position in VIR in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.96M in Q2 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • ProShare Advisors held 23,043 shares of Vir Biotechnology worth $235K as of Q2 2026.
  • ProShare Advisors bought 1,275 Vir Biotechnology shares in Q2 2026, an estimated $12.1K.
  • Vir Biotechnology made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1555 holding.
  • ProShare Advisors first reported a position in Vir Biotechnology in Q2 2020 and has held it in 25 quarters since.
  • ProShare Advisors's Vir Biotechnology position peaked at $1.96M in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.